title: [Effective analysis of non-surgical combined treatments for laryngeal organ preservation in locally advanced laryngeal carcinoma].
abstract: OBJECTIVE
  To evaluate the therapeutic effects, larynx preservation and adverse events of non-surgical combined treatments for laryngeal organ preservation in locally advanced laryngeal squamous cell carcinomas(SCCs).
  
  
  METHODS
  Forty-six patients with locally advanced laryngeal carcinoma (T2-4, N0-N3) were treated individually with non-surgical combined treatments for larynx preservation (LP). These treatments included concurrent chemoradiotherapy (CCRT)(±epidermal growth factor receptor (EGFR) inhibitor), induction chemotherapy (ICT) followed by CCRT(± EGFR inhibitor), or concurrent radiotherapy and EGFR inhibitor. Radiation therapy was given to a total dose of 60-70 Gy. The Kaplan-Meier method was used to determine the overall survival. Side-effects were evaluated with the established Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria.
  
  
  RESULTS
  The average follow-up time was 31.8 months (range 6-95 months). All patients completed the planned radiotherapy without treatment breaks, and 45(97.8%) of 46 patients completed the planned chemotherapy.The 3-year and 5-year overall survival rates were 87.3%and 67.2%, respectively.The 5-year larynx preservation rate was 100.0%. The 3-year and 5-year progression free survival rates were 95.1% and 87.7%, respectively. The most common acute side effect in grade 3 was oropharyngeal mucositis. After treatment, tracheotomy was still required in 2 patients with glottis cancer for laryngeal edema or stenosis. No patient depended on a percutaneous gastrostomy and experienced speech impairment.
  
  
  CONCLUSIONS
  Patients with locally advanced laryngeal cancer can be offered non-surgical combined treatments for laryngeal preservation and the high quality of life, showing a higher laryngeal preservation survival rate with minimal toxicities.
authors.affiliation: Department of Otorhinolaryngology Head and Neck Surgery, Hospital of People's Liberation Army, Beijing 100853, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Yan
authors.affiliation: Department of Otorhinolaryngology Head and Neck Surgery, Hospital of People's Liberation Army, Beijing 100853, China.
authors.forename: Xinxin
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Otorhinolaryngology Head and Neck Surgery, Hospital of People's Liberation Army, Beijing 100853, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Ma
authors.affiliation: Department of Otorhinolaryngology Head and Neck Surgery, Hospital of People's Liberation Army, Beijing 100853, China.
authors.forename: Mingbo
authors.initials: M
authors.lastname: Liu
authors.affiliation: Department of Otorhinolaryngology Head and Neck Surgery, Hospital of People's Liberation Army, Beijing 100853, China.
authors.forename: Nanxiang
authors.initials: N
authors.lastname: Chen
authors.affiliation: Department of Otorhinolaryngology Head and Neck Surgery, Hospital of People's Liberation Army, Beijing 100853, China.
authors.forename: Jialing
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Otorhinolaryngology Head and Neck Surgery, Hospital of People's Liberation Army, Beijing 100853, China.
authors.forename: Wenming
authors.initials: W
authors.lastname: Wu
authors.affiliation: Department of Otorhinolaryngology Head and Neck Surgery, Hospital of People's Liberation Army, Beijing 100853, China.
authors.forename: Deliang
authors.initials: D
authors.lastname: Huang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy; D059248:Chemoradiotherapy; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D007830:Larynx; D059351:Organ Sparing Treatments; D011788:Quality of Life; D000077195:Squamous Cell Carcinoma of Head and Neck; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents